Gogo Inc. announced its Q3 2026 results with total revenue of $213.2 million and a net loss of $3.2 million, reflecting its ongoing transformation into a global satellite connectivity provider. The company extended and amended its $600 million Term Loan B to 2030, enabling further debt reduction and strategic flexibility. Additionally, Gogo secured a 10-year renewal of its exclusive nationwide air-to-ground spectrum license through 2036, supporting future growth in business and military aviation markets. The company reiterated its 2026 financial guidance, expecting revenue between $870 million and $895 million and adjusted EBITDA of $175 million to $185 million.
Gogo's third quarter results provide context for readers following technology companies. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 06, 2026 19:42 WIB: out of 150 priced stocks, 86 rose and 60 fell. Notable movers include Applied Digital Corporation (APLD) with a price of USD 15.56 and a 1-day change of +9.81%, Aehr Test Systems (AEHR) at USD 53.59 with a +9.01% change, and United Microelectronics Corp (UMC) at USD 14.57 with a +8.89% change.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
